Imugene completes recruitment to HER-Vaxx Phase 2 trialim
Filed with ASX · · 2 pages · English
Story so far
Earlier from Imugene
- Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial
- Imugene Receives $4.82 million R&D Tax Incentive
- Imugene First Patient Dosed in PD1-VAXX Clinical Trial
- Imugene HER Vaxx shows positive Overall Survival in trial
- Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
Later from Imugene
- Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial
- Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial
- Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting
- S&P DJI Announces March 2021 Quarterly Rebalance
- Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene